1. Pink Sheet

The Quality Lowdown: Recalls And Shortages

 
• By Bowman Cox

EpiPens get new lease on life, though not like nationally stockpiled AtroPens got, while B. Cepacia humbles King Bio and valsartan impurity rouses science to action. More drug recalls, more warning letters, more import alerts are announced, while a new counterfeit detector makes its debut.

chemistry

Drug recalls and shortage alleviation efforts are back in the news.

In mid-August, US FDA eased shortages by giving four more months to expiring Mylan NVEpiPen (epinephrine) auto injectors based...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Compliance